STOCK TITAN

Annexon (ANNX) Stock News, Dec 2023-Mar 2024

ANNX NASDAQ

Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.

Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.52%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.51%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.51%
Tags

FAQ

What is the current stock price of Annexon (ANNX)?

Annexon (ANNX) last closed at $3.41.

What is the market cap of Annexon (ANNX)?

The market cap of Annexon (ANNX) is approximately $650.5M.